Biologics To Dominate 2028 Medicare Negotiation Cycle As Eligibility Expands To Part B

 
• By Cathy Kelly
  
Several Part B immunologics are expected to be targeted for Medicare price negotiation. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Medicare